Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Clinical trials sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, explained in plain language.
A biopharmaceutical company focused on CAR T-cell therapies for cancer, now part of Bristol-Myers Squibb.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could CAR t cells tame autoimmune brain diseases? Results expected Jul 2027 (estimated)
-
Engineered immune cells take on lupus and other autoimmune diseases
Disease control OngoingThis early-stage trial is testing a new treatment called CC-97540, which uses a patient's own immune cells modified to target and destroy faulty immune cells. It is for people with severe forms of lupus, myositis, scleroderma, or rheumatoid arthritis that have not improved with s…
Phase 1 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Could CAR t cells tame autoimmune brain diseases?
Disease control OngoingThis early-stage trial tests a new treatment called CC-97540, which uses a patient's own immune cells engineered to target and destroy harmful immune cells. The study includes 120 people with relapsing or progressive multiple sclerosis or refractory myasthenia gravis. The main go…
Phase 1 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Engineered immune cells aim to tame lupus without daily pills
Disease control OngoingThis phase 2 trial tests a one-time treatment called CC-97540, made from a patient's own immune cells engineered to target and calm the overactive immune system in lupus. The study enrolls 89 adults with active lupus (including kidney inflammation) who have not responded well to …
Phase 2 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
CAR T-Cell therapy trial for lymphoma pulled before it started
Disease control CancelledThis study was designed to compare a CAR T-cell therapy called Liso-cel against standard treatments for adults with follicular lymphoma that had come back or stopped responding to previous therapy. The trial was a large Phase 3 study planned at multiple hospitals worldwide, but i…
Phase 3 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC